PE20020959A1 - Derivados quimicos y su aplicacion como agentes antitelomerasa - Google Patents

Derivados quimicos y su aplicacion como agentes antitelomerasa

Info

Publication number
PE20020959A1
PE20020959A1 PE2002000227A PE2002000227A PE20020959A1 PE 20020959 A1 PE20020959 A1 PE 20020959A1 PE 2002000227 A PE2002000227 A PE 2002000227A PE 2002000227 A PE2002000227 A PE 2002000227A PE 20020959 A1 PE20020959 A1 PE 20020959A1
Authority
PE
Peru
Prior art keywords
amino
nil
methyl
triazine
quinoli
Prior art date
Application number
PE2002000227A
Other languages
English (en)
Inventor
Patrick Mailliet
Abdelazize Laoui
Gilles Doerflinger
Francois Hamy
Thomas Caulfield
Jean-Louis Mergny
Jean-Francois Riou
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0103916A external-priority patent/FR2822468B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PE20020959A1 publication Critical patent/PE20020959A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN AGENTE REPARTIDOR LIGADO A GRUPOS AMINO AROMATICOS DE FORMULA: CICLOAROMATICO NITROGENADO-NR3-DISTRIBUIDOR-NR'3-CICLO AROMATICO; DONDE CICLOAROMATICO NITROGENADO ES QUINOLEINA, ISOQUINOLEINA, BENZAMIDINA, PIRIDINA; CICLO AROMATICO REPRESENTA QUINOLEINA SUSTITUIDO POR N(Ra)(Rb); BENZAMIDINA, PIRIDINA, FENILO, HETEROCICLO MONO, BI, TRICICLICO; Ra, Rb SON H, ALQUILO C1-C4, ALCOXI C1-C4. R3, R'3 SON TRIAZINA SUSTITUDO, DIAZINA SUSTITUIDO. SON COMPUESTOS PREFERIDOS 2,4-BIS-(4-DIMETILAMINO-2-METIL-QUINOLI-6-NIL)AMINO-6-(3-DIMETILAMINO-PROPIL)AMINO-[1,3,5]TRIAZINA; 2,4,6-TRIS-(4-AMINO-2-METIL-QUINOLI-6-NIL)AMINO-[1,3,5]TRIAZINA, 2,4-BIS-(4-AMINO-2-METIL-QUINOLI-6-NIL)AMINO-6-(4-DIMETILAMINO-2-METIL-QUINOLI-6-NIL)-AMINO-[1,3,5]TRIAZINA, 2,4-BIS-(4-DIMETILAMINO-2-METIL-QUINOLI-6-NIL)AMINO-6-((1-METIL-PIPERIDI-4-NIL)-[1,3,5]TRIAZINA, ENTRE OTROS. LOS COMPUESTOS NO NUCLEOTIDOS INTERACTUAN CON ESTRUCTURAS ESPECIFICAS DEL ADN O ARN, SON INHIBIDORES DE TELOMERASA VIA LA ESTABILIZACION DE G-CUADRUPLEXAS, Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE CANCER
PE2002000227A 2001-03-23 2002-03-22 Derivados quimicos y su aplicacion como agentes antitelomerasa PE20020959A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0103916A FR2822468B1 (fr) 2001-03-23 2001-03-23 Derives chimiques et leur application comme agent anti-telomerase
FR0110370 2001-08-02

Publications (1)

Publication Number Publication Date
PE20020959A1 true PE20020959A1 (es) 2002-12-17

Family

ID=26212933

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000227A PE20020959A1 (es) 2001-03-23 2002-03-22 Derivados quimicos y su aplicacion como agentes antitelomerasa

Country Status (11)

Country Link
EP (1) EP1373252A1 (es)
JP (1) JP2004524349A (es)
AR (1) AR034297A1 (es)
AU (1) AU2002251140B2 (es)
CA (1) CA2442012A1 (es)
CO (1) CO5380035A1 (es)
IL (2) IL158056A0 (es)
MX (1) MXPA03008269A (es)
MY (1) MY130957A (es)
PE (1) PE20020959A1 (es)
WO (1) WO2002076975A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002314252A1 (en) * 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004001018A2 (en) * 2002-06-25 2003-12-31 The Center For Blood Research, Inc. Vacuolins
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
NZ563245A (en) * 2005-05-19 2011-04-29 Prometic Biosciences Inc Triazine compounds and compositions thereof for the treatment of cancers
EP2046763A2 (en) * 2006-07-31 2009-04-15 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
JP5282091B2 (ja) * 2007-07-25 2013-09-04 ブリストル−マイヤーズ スクイブ カンパニー トリアジンキナーゼ阻害剤
FR2948686B1 (fr) * 2009-07-30 2011-08-19 Biomerieux Sa Nouveaux substrats de peptidase
JP7284518B2 (ja) * 2018-03-20 2023-05-31 国立大学法人広島大学 テロメア結合タンパク質を阻害する化合物、及びそれを含むテロメア結合タンパク質阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
HUP0204429A2 (hu) * 1999-11-29 2003-04-28 Aventis Pharma S.A. Aril-amin-származékok és alkalmazásuk antitelomeráz hatású szerként
AU2003244463A1 (en) * 2002-02-05 2003-09-02 Yamanouchi Pharmaceutical Co., Ltd. 2,4,6-triamino-1,3,5-triazine derivative

Also Published As

Publication number Publication date
AU2002251140B2 (en) 2007-03-15
CO5380035A1 (es) 2004-03-31
MXPA03008269A (es) 2004-10-15
IL158056A0 (en) 2004-03-28
EP1373252A1 (fr) 2004-01-02
AR034297A1 (es) 2004-02-18
MY130957A (en) 2007-07-31
CA2442012A1 (fr) 2002-10-03
WO2002076975A1 (fr) 2002-10-03
JP2004524349A (ja) 2004-08-12
IL158056A (en) 2010-02-17

Similar Documents

Publication Publication Date Title
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20020959A1 (es) Derivados quimicos y su aplicacion como agentes antitelomerasa
PE20010912A1 (es) Derivados arilamina y su aplicacion como agentes antitelomerasa
DE602004023838D1 (de) Hemmer der akt aktivität
DE602004026047D1 (de) Hemmer der akt aktivität
BRPI0514371A (pt) 2, 4 di (aminofenil) pirimidina como inibidores de plk
DK1333833T3 (da) Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
GEP20053660B (en) Novel Tyrosine Kinase Inhibitors
PE20020305A1 (es) 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA
DE60227492D1 (de) Hemmstoffe der akt aktivität
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CO5700778A2 (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
NO20035583D0 (no) Imidazo` 1,2-A pyridinderivater for profylakse og behandling av herpes virale infeksjoner
PA8501801A1 (es) Inhibidores triciclicos de polimerasas (adp - polirribosas)
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
ES2172945T3 (es) Imidazotriazinonas sustituidas en 2 con fenilo como inhibidores de fosfodiesterasas.
GT200100016A (es) Pirido[2,3,-d]pirimidin-2,7-diaminas inhibidoras de cinasas.
EP1633740A4 (en) CHEMICAL COMPOUNDS
ATE452896T1 (de) C3-cyanoepothilonderivate
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
GT200100251A (es) Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida
ES2079068T3 (es) 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed